Company / Operating Cash Flow
REGENXBIO Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$124.0M
FY2025
5-year range
-$218.4M / -$107.7M
FY2021-FY2025
Trend
+28.4%
vs FY2024
Sector context
#135 of 216
Health Care
What the data says
At -$124M, REGENXBIO Inc.'s operating cash flow ranks #135 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$218M in FY2023 to $105M in FY2020.
Based on SEC 10-K filings.
-$124M in FY2025.
Improved from -$218M to -$124M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#135 of 216 in Health CareTop 62% of 216This company -$124.0M Sector average $659.0M
▼
-118.8% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 28.4% year-over-year.
- Ranks #135 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$124.0M | +28.4% |
| FY2024 | -$173.1M | +20.7% |
| FY2023 | -$218.4M | -5.3% |
| FY2022 | -$207.5M | -92.6% |
| FY2021 | -$107.7M | -202.9% |
| FY2020 | $104.6M | +280.5% |
| FY2019 | -$58.0M | -155.4% |
| FY2018 | $104.6M | +280.5% |
| FY2017 | -$58.0M | -2317.3% |
| FY2016 | -$2.4M | +20.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026